The Southeast Asia molecular diagnostics market is projected to reach USD 891.9 million by 2031 from an estimated USD 528.3 million in 2024, at a CAGR of 7.8% during the forecast period.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the Southeast Asia molecular diagnostics market is driven by several factors, including the rising geriatric population, increasing prevalence of communicable & non-communicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditure. However, the lack of harmonization of the medical device regulations across Southeast Asian countries and the high costs of molecular diagnostics tests restrain the growth of the market.
Furthermore, emerging medical tourism in Southeast Asian countries and increasing focus on companion diagnostics are expected to create growth opportunities for the players in this market. However, A shortage of skilled professionals are major challenges for market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over years (2021-2024). Some of the prominent players operating in the Southeast Asia molecular diagnostics market are are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), Sansure Biotech Inc. (China), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Abbott Laboratories (U.S.), Qiagen N.V. (Netherlands) and Xiamen Zeesan Biotech Co., Ltd. (China).
The Southeast Asia molecular diagnostics market is segmented by offering, test type, technology, application, end user and geography.
Based on offering, the Southeast Asia molecular diagnostics market is segmented into kits & reagents, instruments and software & services. In 2024, the kits & reagents segment accounted for the largest share of 68.7% of the Southeast Asia molecular diagnostics market. The segment's large market share is attributed to the commercial availability of a diverse range of diagnostic reagents & consumables, the availability of disease-specific test kits & assays, and growing awareness regarding early disease diagnosis.
Based on test type, the Southeast Asia molecular diagnostics market is segmented into laboratory tests and point-of-care tests. In 2024, the laboratory tests segment is accounted for the larger share of the Southeast Asia molecular diagnostics market. The large market share of this segment is attributed to this conventional method involves clinicians to collect patient samples and send them to diagnostics laboratories for analysis. The laboratory tests offer various advantages such as high accuracy, reliability, sensitivity and specificity. These tests are cost-effective than point-of-care tests, which is widely adopted in healthcare settings and preferred by patients.
Based on technology, the Southeast Asia molecular diagnostics market is segmented into Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT), microarrays, sequencing, mass spectrometry and other technologies. In 2024, the Polymerase Chain Reaction (PCR)segment is expected to account for the largest share of 38.8% of the Southeast Asia molecular diagnostics market. The large market share of this segment is attributed to its versatility, accuracy and broader application in diagnostics and research. Indonesia expanded its PCR capabilities during COVID-19 period through multifaceted testing strategies.
Based on application, the Southeast Asia molecular diagnostics market is segmented into infectious diseases, oncology, respiratory diseases, genetic testing, neurological disease, cardiovascular diseases and other applications. The infectious diseases segment is further sub-segmented into respiratory diseases, hepatitis, HIV, chlamydia trachomatis/neisseria gonorrhoeae, human papillomavirus (HPV), healthcare-associated infections (HAIS) and other infectious diseases. In 2024, the infectious diseases segment is expected to account for the largest share of 44.2% of the Southeast Asia molecular diagnostics market. The large market share of this segment is attributed to the high communicable and causes epidemics, requires diagnosis to prevent the spread. Molecular diagnostics is used to identify and manage these diseases due to its rapid results, sensitivity and specificity, identification of resistant microorganisms, and correlation to disease severity. All these features contribute to the timely clinical decisions and infection control.
Based on geography, the Southeast Asia molecular diagnostics market is segmented into Indonesia, Vietnam, Thailand, Singapore, Philippines, Malaysia and Rest of Southeast Asia. In 2024, Singapore is expected to account for the largest share of 23.3% of the Southeast Asia molecular diagnostics market, followed by Indonesia (20.3%), and Vietnam (18.3%). Indonesia’s major market share is attributed to the Improving healthcare infrastructure, growing healthcare spending, and high burden of infectious and non-infectious diseases.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the Southeast Asia molecular diagnostics market is driven by several factors, including the rising geriatric population, increasing prevalence of communicable & non-communicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditure. However, the lack of harmonization of the medical device regulations across Southeast Asian countries and the high costs of molecular diagnostics tests restrain the growth of the market.
Furthermore, emerging medical tourism in Southeast Asian countries and increasing focus on companion diagnostics are expected to create growth opportunities for the players in this market. However, A shortage of skilled professionals are major challenges for market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over years (2021-2024). Some of the prominent players operating in the Southeast Asia molecular diagnostics market are are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), Sansure Biotech Inc. (China), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Abbott Laboratories (U.S.), Qiagen N.V. (Netherlands) and Xiamen Zeesan Biotech Co., Ltd. (China).
The Southeast Asia molecular diagnostics market is segmented by offering, test type, technology, application, end user and geography.
Based on offering, the Southeast Asia molecular diagnostics market is segmented into kits & reagents, instruments and software & services. In 2024, the kits & reagents segment accounted for the largest share of 68.7% of the Southeast Asia molecular diagnostics market. The segment's large market share is attributed to the commercial availability of a diverse range of diagnostic reagents & consumables, the availability of disease-specific test kits & assays, and growing awareness regarding early disease diagnosis.
Based on test type, the Southeast Asia molecular diagnostics market is segmented into laboratory tests and point-of-care tests. In 2024, the laboratory tests segment is accounted for the larger share of the Southeast Asia molecular diagnostics market. The large market share of this segment is attributed to this conventional method involves clinicians to collect patient samples and send them to diagnostics laboratories for analysis. The laboratory tests offer various advantages such as high accuracy, reliability, sensitivity and specificity. These tests are cost-effective than point-of-care tests, which is widely adopted in healthcare settings and preferred by patients.
Based on technology, the Southeast Asia molecular diagnostics market is segmented into Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT), microarrays, sequencing, mass spectrometry and other technologies. In 2024, the Polymerase Chain Reaction (PCR)segment is expected to account for the largest share of 38.8% of the Southeast Asia molecular diagnostics market. The large market share of this segment is attributed to its versatility, accuracy and broader application in diagnostics and research. Indonesia expanded its PCR capabilities during COVID-19 period through multifaceted testing strategies.
Based on application, the Southeast Asia molecular diagnostics market is segmented into infectious diseases, oncology, respiratory diseases, genetic testing, neurological disease, cardiovascular diseases and other applications. The infectious diseases segment is further sub-segmented into respiratory diseases, hepatitis, HIV, chlamydia trachomatis/neisseria gonorrhoeae, human papillomavirus (HPV), healthcare-associated infections (HAIS) and other infectious diseases. In 2024, the infectious diseases segment is expected to account for the largest share of 44.2% of the Southeast Asia molecular diagnostics market. The large market share of this segment is attributed to the high communicable and causes epidemics, requires diagnosis to prevent the spread. Molecular diagnostics is used to identify and manage these diseases due to its rapid results, sensitivity and specificity, identification of resistant microorganisms, and correlation to disease severity. All these features contribute to the timely clinical decisions and infection control.
Based on geography, the Southeast Asia molecular diagnostics market is segmented into Indonesia, Vietnam, Thailand, Singapore, Philippines, Malaysia and Rest of Southeast Asia. In 2024, Singapore is expected to account for the largest share of 23.3% of the Southeast Asia molecular diagnostics market, followed by Indonesia (20.3%), and Vietnam (18.3%). Indonesia’s major market share is attributed to the Improving healthcare infrastructure, growing healthcare spending, and high burden of infectious and non-infectious diseases.
Key questions answered in the report:
- Which are the high-growth market segments based on offering, test type, technology, application, and end user?
- What was the historical market for Southeast Asia molecular diagnostics market?
- What are the market forecasts and estimates for the period 2024-2031?
- What are the major drivers, restraints, and opportunities in the Southeast Asia molecular diagnostics market?
- Who are the major players in the Southeast Asia molecular diagnostics market?
- What is the competitive landscape like?
- What are the recent developments in the Southeast Asia molecular diagnostics market?
- What are the different strategies adopted by the major players in the Southeast Asia molecular diagnostics market?
- What are the key geographic trends, and which are the high-growth countries?
- Who are the emerging players in the Southeast Asia molecular diagnostics market, and how do they compete with the other players?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Southeast Asia Molecular Diagnostics Market Assessment-by Offering
6. Southeast Asia Molecular Diagnostics Market Assessment-by Test Type
7. Southeast Asia Molecular Diagnostics Market Assessment-by Technology
8. Southeast Asia Molecular Diagnostics Market, by Application
9. Southeast Asia Molecular Diagnostics Market Assessment-by End User
10. Southeast Asia Molecular Diagnostics Market Assessment-by Country
11. Competitive Landscape
12. Company Profiles
List of Tables
List of Figures
Companies Mentioned
- Illumina Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Hologic Inc. (U.S.)
- Sansure Biotech Inc. (China)
- Agilent Technologies Inc. (U.S.)
- Danaher Corporation (U.S.)
- Abbott Laboratories (U.S.)
- Qiagen N.V. (Netherlands)
- Xiamen Zeesan Biotech Co. Ltd. (China).
